Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Enovis makes medical devices for surgery, recovery, and pain relief, sold to doctors and hospitals.
Enovis makes the hardware that helps people move again. It sells implants for reconstructive surgery, like artificial knees and hips, along with the braces, boots, and therapy machines a patient uses during the long recovery. It also sells devices aimed at pain, including products that treat injuries without surgery. The customers are the healthcare professionals — orthopedic surgeons, physical therapists, and hospitals — who choose these tools and then bill insurers or patients for using them.
The company is really two businesses stitched together. One is prevention and recovery, which makes things like walking boots, knee braces, and cold-therapy machines that a physical therapist might hand you after an injury. The other is reconstructive surgery, where the company designs the joint implants a surgeon puts into your body. That second side is the harder, more regulated, and more profitable one, and it is where the company has been pushing to grow by taking share from bigger rivals like Zimmer Biomet and Stryker. Enovis was not always called that. It was spun out of Colfax in 2021, when the industrial conglomerate split its welding business off from its medical device arm, and the medical side took the Enovis name. Since then the company has been buying up smaller device makers to bulk up its surgical division, most notably spending roughly $850 million to buy LimaCorporate, an Italian maker of shoulder and other joint implants. That deal is the clearest statement of strategy: get more products to sell to the same surgeons.
The appeal of a business like this is that surgery is a sticky relationship. Once a surgeon learns a company's implants and the instruments that go with them, switching is a hassle, so device makers fight hard to win a surgeon early and then keep them. The risk is that hospitals and insurers keep squeezing prices, and the big players are much bigger. Enovis is the scrappy challenger trying to buy its way into a seat at the operating table.
Saved answer · last researched 15 Nov 2026